# Biostate AI

General-purpose biomedical AI to help 90% of people live to 90

- Canonical URL: https://wefunder.com/biostate.ai
- Entity ID: wefunder:company:168070
- Last updated: 2026-06-07T05:03:14Z
- Generated at: 2026-06-07T13:04:02Z

## Quick facts
- $20M raised from leading VCs including Accel, Matter Venture Partners, InfoEdge Ventures, Vision Plus, and Caltech Fund.
- Repeat Founder: previously built $100M+ funded genomic platform with $20M+ revenue (2022).
- 30+ clinical collaborations with top hospitals including Harvard Med School, MD Anderson, Cornell… Accessing 100,000+ patient samples worldwide.
- Active clinical research programs in Leukemia, Melanoma, Lung cancer, Diabetes, Lupus, Multiple Sclerosis, and Coronary Artery Disease
- 15+ Patented technology to reduce RNA & DNA testing cost by 80%+
- Our AI scientist platform (K-Dense) outperforms ChatGPT-5, Claude, Gemini by 60%+.
- Revolutionizing Precision medicine and Multi-omics, $100B+ markets.
- Headquarter in Houston and palo alto. Subsidiaries in India, China, and Saudi Arabia

## Active fundraises
- wefunder:fundraise:152566: 4(a)(6) successful (USD)
- wefunder:fundraise:127927: 4(a)(6) successful (USD)
- wefunder:fundraise:152565: 4(a)(6) open (USD)
- wefunder:fundraise:127926: 4(a)(6) successful (USD)

## Story
Why Biostate AI?Today, pharma companies spend billions of dollars and multiple years to develop new drugs that benefit less than 20% of patients for each hyper-narrow disease. At Biostate, we believe that with the power of big data and modern AI, we can build a general purpose biomedical AI that can help 90% of humanity live to 90 years old by understanding and helping cure all diseases.Since its founding in 2023, Biostate has become a global constellation of organizations spanning 4 countries. We have established partnerships with dozens of leading hospitals including Harvard Medical School, MD Anderson Cancer Center, Cornell Weill Medical School, Peking Renmin Hospital (China), and Narayana Health (India).Through these collaborations, we can obtain real-world clinical data to train our predictive medical AI, N-act. Our active clinical research programs initially focus on leukemia, lung cancer, melanoma, diabetes, lupus, multiple sclerosis, and heart disease.The N-act model helps identify early warning patterns that standard tests often miss. These insights enable doctors to make earlier, better-informed decisions and ultimately improve care for millions of patients worldwide.Biostate's Series A (2025) was led by Accel (Series A investors in Facebook, Scale AI, Slack, and Discord), and Biostate's earliest investors include Dario Amodei (co-founder/CEO of Anthropic), Emily Leproust (co-founder/CEO of Twist Bioscience), and the California Institute of Technology.These returns represent unrealized gains based on valuation increases from subsequent financing rounds. Previous investors have not yet received realized returns. Returns are not guaranteed. From its 2023 Seed round, Biostate's investors have seen up to +210% gain on the value of their investments. These top investors believe and support Biostate's vision of a future of healthy living – will you join them?The World Is Losing Billions of Healthy YearsToday, the average global life expectancy is about 71 years (WHO). Most people lose nearly two decades of healthy life not because their diseases were incurable, but because doctor prescribe treatment for the “average” patient instead of specifically optimized for them. Precision medicine has the power to change this, but it is currently accessible to less than 5% of the world.If we can find a way to extend healthy lifespan to 90, the impact will be enormous: adding 19 extra healthy years to each of Earth’s 8 billion people creates a combined 150 billion healthy years of life.According to the ICER, each Quality-Adjusted Life Year (QALY) is worth $100,000–$150,000. That means we will generate over $3,000 trillion of global value, 25× the current annual world GDP.This is why our mission matters.Biostate has been working on the innovation of multiomics testing and advanced AI technologies to achieve this mission, and allowing your grandparents, your parents, and you to live longer and happier without battling the specter of disease.DNA and RNA sequencing technologies used today were invented in a different era and not intended to scale to millions of people. Genetic tests like Foundation One for cancer have a price tag of over $3000 to analyze 500 genes. We've invented and deployed technology to do genetic analysis for less than $50, and on 30,000 genes rather than 500. This uniquely allows us to scale data collection to millions of patient samples, with proper informed consent and physician support, in order to train powerful medical AI.10× lower cost than traditional RNA sequencing 10× less input required: one FFPE curl or 1 mL of plasma can uncover 30,000+ genesWorks on damaged, degraded, or ultra-small samples that normally fail in standard pipelines8x lower cost than traditional DNA sequencing (Higher margin)>95% uniform coverage at 30× depth, high diagnostic reliability260% improvement in notoriously difficult GC-rich regionsModern general-purpose AI models were not built to analyze terabytes of human molecular data. DNA or RNA sequencing data from a single person is usually 5000x larger than ChatGPT's working memory(100,000 words). That’s why we built K-Dense - an autonomous AI scientist specializing in bio/medicine and outperforming ChatGPT, Gemini, and Deepseek by 60%.Working with Dr. David Sinclair, one of the world’s leading aging researchers, K-Dense helped build one of the most accurate models for predicting biological age. In the process, K-Dense discovered four new RNA biomarkers of aging, uncovering biology that had never been documented before.Go to MarketOur pricing is simple.RNA tests cost $80 per sample. DNA tests cost $125 per sample. Gross margins are above 70%.In the U.S. alone, cancer diagnostic testing represents a market of over $70B, with more than $25B per year coming from repeat tests, and this market continues to grow each year.This is only part of a larger opportunity across many additional disease areas where Biostate’s technology can create substantial value.With operations across the United States, China, India, and the Middle East, Biostate operates inside the world’s fastest-growing healthcare markets:China: 1.4B population; rapidly developing pharmaceutical industry building new drugsIndia: 1.4B population; world's greatest manufacturer of affordable generic and biosimilar drugsSaudi Arabia: Spiritual center of the 1.8B Muslim world with over 100 million worldwide pilgrims per year; strong government initiatives and incentives to modernize health through Vision 2030.No other precision-medicine company combines global wet labs, AI platforms, and multiomic pipelines across these regions exactly like us.Our leadership team combines deep scientific expertise, proven company-building experience, and global operational leadership. Led by a repeat founder with a strong track record in molecular diagnostics and supported by seasoned financial and technical executives, the team brings together strengths across biotech, AI, and international markets—positioning Biostate.ai to execute at scale and translate cutting-edge science into real-world impact.This advisory board brings together world-class clinicians, researchers, and innovators from leading institutions to guide and support Biostate.ai’s mission.Backed by expertise across genomics, cancer, cardiovascular, autoimmune, and rare diseases, these advisors provide critical scientific, clinical, and strategic insight—ensuring our technology is credible, clinically relevant, and built to scale real-world impact.Multi-Engine Revenue GrowthBiostate AI is scaling through multiple high-margin growth engines: U.S. clinical diagnostics, proprietary AI software (K-Dense), and expansion across India, China, and the Middle East.Forward-looking projections are not guaranteed. The $10.5M projection includes both organic growth and strategic expansion. Organically, we project ~$1.5M in 2026 for Biostate, and ~$3M on a consolidated basis including subsidiaries and spinouts. The higher projection reflects our strategy to expand sequencing capacity and selectively acquire profitable sequencing labs.Revenue is projected to grow from $10.5M in 2026 to $180M by 2029, driven by repeat testing, AI licensing, and global market access. With gross margins above 70%, this growth supports strong operating leverage and long-term enterprise value.Join us in creating a future where precision medicine works for everyone.

## FAQ
1. **Hi, I'm interested, but quite concerned about your burn rate of $340K per month! Your cash in hand was $2,000,000, as of December 2024. Now that we're at the beginning of February 2025, that would leave $1.66M which covers a little less than 5 months of expenses. By your raise...**
   - We cannot disclose ongoing other fundraising activities, but we have no plans for cuts and have actually expanded the team by roughly 7 people in the past 2 months.
2. **Your cause is admirable but, you're going to be so outclassed and outcompeted that by the time you are ready to make a profit, you won't have an ounce of investor confidence. Even then the risk reward is, what, at best 50x in 10 years and on the way you will dilute early inves...**
   - Hi Timmy, - With our patented BIRT and PERD technologies, we have an 8x lower cost than ALL competitors, and achieve over 80% gross margins on over 25,000 samples. - Our point about not being profitable for up to 14 years is about net margin/profit, because all of our fundraises and gross profits will be going towards R&D to help people live longer. - Our valuation as of May 2025, assigned by Accel (earliest investors in Facebook and Discord) was $62M. Since that time, we have created sig...
3. **wow, I was in until I saw the no profit for 14 years mentioned by timmy. I have never seen that time frame in my life and I have over 160 companies in my portfolio and obviously looked at plenty more. that is beyond long term, some of your investors may kick the bucket before ...**
   - Hi John, "Unprofitable for 14 years" is the good outcome, actually, kind of like how Amazon was unprofitable from 1994 to 2003. If the fundraising environment sours, we have the ability to become profitable (and we do have profitable business units). But that will slow our collection of human samples and multiomics datasets, which means that our ultimate goal of treating all diseases becomes farther away.
4. **Hi. Congrats on your success so far. A few questions, please: 1. You mention pricing for RNA and DNA sequencing tests. Are you monetizing any of your AI tools/services? 2. I see that K-Dense is a spinout of Biostate. Does an investment in Biostate through this campaign also en...**
   - Hi Brian, thanks for your question. 1. Yes, please visit k-dense.ai to try it out! 2. Yes, K-Dense is currently majority owned by Biostate AI, so you get indirect ownership in K-Dense. 3. K-Dense and DNA sequencing are currently available. N-Act requires a prospective clinical trial/study before commercialization; we hope to start the study later this year and complete before end of 2027. 4. The most direct competitor is Tempus AI (nasdaq: tem), an $8B company. They are doing precision medici...
5. **Thanks for your responses, Dave. One more question, if I may. Your chart shows a revenue projection of $180 million in 2029. Is this figure cumulative? Or do you project to bring in $180 million in revenues in 2029 alone?**
   - Hi Brian, thanks for your question. Multiple Sclerosis (MS) subtyping itself is a $2B / yr market: There are over 1 million Americans affected by this disease, and currently clinicians can only tell when a RRMS has converted to progressive MS 2-5 years after the fact, through MRI scans. A blood test (that we are currently developing) for detecting progressive MS, selling at $2000 / test, and 1 test per year, is $2B / yr. A $180M / yr revenue is estimating a 9% market penetration, which is typ...

## Team
- Dave Zhang (Co-Founder/CEO)
- Jeremy Sobotta (CFO)
- Kutapa Muthanna (CEO, Bayosthiti.AI (India Subsidiary))
- Zoe Zheng (CEO, Baiaosheng (China Subsidiary))
- Mohammad Alkheilewi (CEO, Biostate AI MENA (KSA Subsidiary))

## Q&A
- Q: When will you provide the investment terms? I’m missing the valuation. And where can I find your financials including forecasts? Thanks!
- Q: Your cause is admirable but, you're going to be so outclassed and outcompeted that by the time you are ready to make a profit, you won't have an ounce of investor confidence. Even then the risk reward is, what, at best 50x in 10 years and on the way you will dilute early investors by 1000x. Literally everyone except you are going to lose money. You're asking for millions of millions of dollars and yet you show no patents, no demo and don't even have a valuation. I admit it seems like a great team. But this is a scam, even if it's not, it will soon be equivalent to one, you are already admitting there will be no profit for up to 14 years. And though you might out-innovate the medtech industry for a while, which isn't that much to brag about, you will be done in once they invest in superhuman AI research models, automating your work in an afternoon. I know you won't ever get a monopoly on sequencing and you'll have hundreds of biotech competitors. If you want my advice, fail fast. Sorry for being harsh but please provide an argument why I am wrong.
  - A: Hi Timmy, - With our patented BIRT and PERD technologies, we have an 8x lower cost than ALL competitors, and achieve over 80% gross margins on over 25,000 samples. - Our point about not being profitable for up to 14 years is about net margin/profit, because all of our fundraises and gross profits will be going towards R&D to help people live longer. - Our valuation as of May 2025, assigned by Accel (earliest investors in Facebook and Discord) was $62M. Since that time, we have created significant value in setting up additional clinical collaborations and inventing and patenting new technologies. Our mission is to help people live longer; if you are not interested in investing, we still welcome you to follow our progress!
- Q: Is this an uncapped SAFE?
- Q: hi , regarding the SAFE contract as is says in the wefunder page it is a 15% discount but when opening the contract it is written 85% ? so what is the correct discount rate ? thanks
- Q: What is the goals and steps to achieve them precisely and how do you plan to earn money?
- Q: When is the SAFE expected to convert into stock?
- Q: Hi, When are you closing this round?
- Q: Hi, I'm interested, but quite concerned about your burn rate of $340K per month! Your cash in hand was $2,000,000, as of December 2024. Now that we're at the beginning of February 2025, that would leave $1.66M which covers a little less than 5 months of expenses. By your raise end date of April 30, 2025, you will have burned through another $1.02M leaving only $640K in your coffers. Thus even if you secure your maximum $1.235M by that date, you’ll have only ~$1.875M - which at your current burn rate is only 5 and a half months. What measures are you taking to cut your burn rate? It would appear that something really needs to change in order to survive. Please advise. Thanks so much. Blessings
  - A: We cannot disclose ongoing other fundraising activities, but we have no plans for cuts and have actually expanded the team by roughly 7 people in the past 2 months.
- Q: Hi. Congrats on your success so far. A few questions, please: 1. You mention pricing for RNA and DNA sequencing tests. Are you monetizing any of your AI tools/services? 2. I see that K-Dense is a spinout of Biostate. Does an investment in Biostate through this campaign also entitle me to K-Dense? 3. I see a technology pipeline on your website. Do you have estimated dates for commercial launch of K-Dense, DNA sequencing tests, and N-Act? 4. Can you speak to any direct competitors in this space and how you believe your company/product is superior? Thanks! Brian
  - A: Hi Brian, thanks for your question. 1. Yes, please visit k-dense.ai to try it out! 2. Yes, K-Dense is currently majority owned by Biostate AI, so you get indirect ownership in K-Dense. 3. K-Dense and DNA sequencing are currently available. N-Act requires a prospective clinical trial/study before commercialization; we hope to start the study later this year and complete before end of 2027. 4. The most direct competitor is Tempus AI (nasdaq: tem), an $8B company. They are doing precision medicine for oncology using DNA, but their approach does not work for autoimmune diseases. DNA is what you're born with and gives you lifetime disease risk. RNA is what is happening to you *right now* and tells you what to do about your disease now.
- Q: theres interest ? if yes can i refuse it for personel religious
  - A: The SAFE is an investment instrument for future equity at a discount and does not carry interest. We are aware of the limitation on interest for investors from the GCC region, and the current structure does not violate sharia law's restriction on riba.
- Q: Thanks for your responses, Dave. One more question, if I may. Your chart shows a revenue projection of $180 million in 2029. Is this figure cumulative? Or do you project to bring in $180 million in revenues in 2029 alone?
  - A: Hi Brian, thanks for your question. Multiple Sclerosis (MS) subtyping itself is a $2B / yr market: There are over 1 million Americans affected by this disease, and currently clinicians can only tell when a RRMS has converted to progressive MS 2-5 years after the fact, through MRI scans. A blood test (that we are currently developing) for detecting progressive MS, selling at $2000 / test, and 1 test per year, is $2B / yr. A $180M / yr revenue is estimating a 9% market penetration, which is typical for between Year 1 and Year 2 of commercialization. The MS subtyping test requires a prospective clinical study to obtain insurance reimbursement, such as from Medicare/Medicaid, and this prospective clinical study is expected to take 1.5-2 years. Of course, we are also working on other diseases beyond MS, but MS is the disease that we have the most progress on so far. See more at biostate.ai/multiple-sclerosis or our recent results on the world's biggest MS molecular study at: medrxiv.org/content/…26.04.19.26351230v1
- Q: wow, I was in until I saw the no profit for 14 years mentioned by timmy. I have never seen that time frame in my life and I have over 160 companies in my portfolio and obviously looked at plenty more. that is beyond long term, some of your investors may kick the bucket before they see a return. is there any particular reason why you don't expect a profit for that long? I see a 100 million valuation. what? how did you determine that.?thanks for your time and congrats on what you have accomplished so far!
  - A: Hi John, "Unprofitable for 14 years" is the good outcome, actually, kind of like how Amazon was unprofitable from 1994 to 2003. If the fundraising environment sours, we have the ability to become profitable (and we do have profitable business units). But that will slow our collection of human samples and multiomics datasets, which means that our ultimate goal of treating all diseases becomes farther away.
- Q: Hi, I see that your round is oversubscribed. Will you be taking all investments? I definitely want to invest again but I'm not sure if you are only accepting a certain amount. Also, for people that invested last year--what is the cap converting to (since it was an uncapped investment at at that time)? I had read somewhere that you said it was $62 that was set by the Accel VC, but I'm not sure so I didn't want to assume. Thanks!
  - A: Hi Jorinda, yes, the last round was 15% discounted to the $62M post-money valuation for Series A led by Accel. We will try to take all investments from the community, subject to the Regulation CF cap.